Gefitinib Usage and Outcomes in Routine Treatment

AstraZeneca157 enrolled

Overview

The purpose of this study is to understand real world gefitinib usage patterns, patient characteristics and outcomes and to present these for a Caucasian population

A multicentre, retrospective chart review study to characterise gefitinib usage and outcomes in routine treatment

Study Type

OBSERVATIONAL

Enrollment

157

Conditions

Lung Cancer

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients who received gefitinib first line in the UK Single Payment Access (SPA) scheme * Locally advanced or metastatic EGFR mutation positive NSCLC * Supplied with first pack of gefitinib prior to 1st January 2012 Exclusion Criteria: * Patient was treated privately (i.e. outside the NHS) * Gefitinib was second-line therapy following treatment failure on a prior therapy

Locations (12)

Queen Elizabeth Hospital

Birmingham, United Kingdom

Velindre Nhs Trust

Cardiff, United Kingdom

Harrogate District Hospital

Harrogate, United Kingdom

Outcomes

Primary Outcomes

Assessment of treatment duration, as a surrogate of Clinical Benefit (CB) in a 'Real World' population treated with gefitinib